Scholar Rock Q2 net loss narrows
SRRK•Cash balance rises on ATM proceeds
The company ended the second quarter with $492 million in cash, boosted by proceeds from its at-the-market, or ATM, program.
Key reported figures and analyst coverage
| Metric | Actual |
|---|---|
| Q2 Net Loss | $109.90 million |
| Q2 Income from Operations | -$108.90 million |
| Q2 Operating Expenses | $108.90 million |
The current average analyst rating on the shares is buy, with 18 strong buy or buy recommendations, no hold, and no sell or strong sell ratings.
The average consensus recommendation for the biotechnology and medical research peer group is buy.
Wall Street's median 12-month price target for Scholar Rock Holding Corporation is $58.00, about 21.2% above its August 5 closing price of $47.87.
